Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 16/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.54 |
| ▸ | GAA | P10253 | 9/20 | 0.53 |
| ▸ | HPGD | P15428 | 7/20 | 0.53 |
| ▸ | GLA | P06280 | 5/20 | 0.53 |
| ▸ | CASP1 | P29466 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3015837 | 0.80 | MAPT (0.52) | MAPTKDM4EALDH1A1GAAHPGD | |
| SCHEMBL1371172 | 0.78 | MAPT (0.41) | MAPTKDM4EALDH1A1GAAHPGD | |
| SCHEMBL6559503 | 0.77 | MAPT (0.63) | MAPTKDM4EALDH1A1GAAHPGD | |
| SCHEMBL3353464 | 0.77 | MAPT (0.68) | MAPTKDM4EALDH1A1GAAHPGD | |
| SCHEMBL2317692 | 0.76 | MAPT (0.67) | MAPTKDM4EALDH1A1GAAHPGD | |
| SCHEMBL69403 | 0.76 | MAPT (0.67) | MAPTKDM4EALDH1A1GAAHPGD | |
| SCHEMBL1821389 | 0.76 | MAPT (0.71) | MAPTKDM4EALDH1A1GAAHPGD | |
| SCHEMBL4260350 | 0.76 | MAPT (0.67) | MAPTKDM4EALDH1A1GAAHPGD | |
| SCHEMBL11904084 | 0.76 | MAPT (0.67) | MAPTKDM4EALDH1A1GAAHPGD | |
| SCHEMBL7957662 | 0.76 | MAPT (0.67) | MAPTKDM4EALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998968-B2 | Substituted pyrimidines and [1,2, 4] triazoles and the use thereof for treating prophylaxis, cardiovascular diseases, metabolic diseases and/or central nervous system diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20110112120-A9 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-05-12 | — | — | US | disclosed |
| US-7803940-B2 | Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20100113780-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-06 | — | — | US | disclosed |
| US-20100105709-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-04-29 | — | — | US | disclosed |
| US-20100056526-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-03-04 | — | — | US | disclosed |
| US-20090176812-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-07-09 | — | — | US | disclosed |
| EP-2074117-A2 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-07-01 | — | — | EP | disclosed |
| US-20080207654-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-08-28 | — | — | US | disclosed |
| WO-2008062905-A2 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112120-A9 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | C1R, C1S, C3AR1 | MAPT 4571/4885KDM4E 4304/4885ALDH1A1 1979/4885 |
| US-20100113780-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | C1R, C1S, C3AR1 | MAPT 4571/4885KDM4E 4304/4885ALDH1A1 1979/4885 |
| US-20100056526-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | CYP11B2, CYP11B1, NR3C2 | MAPT 3015/4885KDM4E 4632/4885ALDH1A1 856/4885 |
| US-20080207654-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | C1R, C3AR1, C1S | MAPT 4434/4885KDM4E 4463/4885ALDH1A1 1982/4885 |
| US-20090176812-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | C1R, C1S, C3AR1 | MAPT 4571/4885KDM4E 4304/4885ALDH1A1 1979/4885 |
| US-20100105709-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | C1R, C1S, C3AR1 | MAPT 4571/4885KDM4E 4304/4885ALDH1A1 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.